Assembly Biosciences (ASMB) Q3 2025 earnings summary

Executive summary

• Focused on developing therapeutics for serious viral diseases, with multiple clinical-stage programs for HSV, HDV, and HBV, and a broad-spectrum NNPI for transplant-related herpesviruses.

• Advanced several clinical studies in 2025, including Phase 1a/1b for two HSV candidates, a Phase 1a for an HDV entry inhibitor, and a Phase 1b for a next-generation HBV capsid assembly modulator.

• Achieved positive interim Phase 1b results for ABI-5366, showing significant reductions in HSV-2 shedding and genital lesion rates in recurrent genital herpes.

• Announced positive interim and topline results across multiple programs, supporting progression to later-stage studies.

• Entered into a significant collaboration and equity investment agreement with Gilead, providing funding and development support.

Financial highlights

• Collaboration revenue was $10.8M for Q3 2025, up 58% year-over-year; $29.8M for the nine months ended September 30, 2025, up 41% year-over-year.

• Net loss for Q3 2025 was $9.2M ($0.72 per share), compared to $9.6M ($1.51 per share) in Q3 2024; net loss for the nine months was $28.2M, compared to $29.8M in the prior year.

• Research and development expenses increased to $16.6M in Q3 2025 (up 23% year-over-year), driven by HSV program activity.

• General and administrative expenses were $5.1M in Q3 2025 (up 19% year-over-year).

• Cash, cash equivalents, and marketable securities totaled $232.6M as of September 30, 2025.

Outlook and guidance

• Management expects the current cash position to fund operations into late 2027, not including potential future payments from Gilead or warrant exercises.

• Ongoing and planned Phase 2 studies for HSV and HDV programs, with further data readouts expected by year-end 2025.

• Initiation of Phase 2 clinical study for ABI-5366 anticipated in mid-2026.

• Collaboration with Gilead may provide additional milestone and royalty payments, extending the cash runway beyond 2028.